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There is a push on nowadays to adopt a personalized approach
o medicine and much of the enthusiasm comes from within the
ancer community. The ﬁrst of two dominant themes is that we
ould better choose a patient’s treatment by having a comprehen-
ive knowledge of the genetic makeup of his or her tumor. DNA
equencing may  identify a ‘targetable’ gene or a pathway of pro-
eins that will render the cancer vulnerable (the relevant drugs are
alled ‘biologics’). The other dominant theme is personalizing pre-
ention. That is, because we do not all share the same inherent risk
or cancer it would be wise to identify and target those at high risk
or special attention. This goes beyond one’s sex and the retention
f susceptible organs (e. g, ovaries or uterus). Factors such as smok-
ng, prior therapeutic radiation, family history and sexual exposure
o papillomavirus are all helpful to identify high-risk individuals,
ut what we are really talking about are the risk factors that we
arry about unawares – but fortunately that we can test for in the
aboratory or in the clinic.
In order for a preventive program to work there has to be a pre-
entive agent on offer. If there is no means of prevention there is
o expectation of beneﬁt. If vitamins prevented cancer we could
eartily recommend them to everybody. No need for personalized
edicine. A healthy lifestyle is good for all and so we  can afford to
e generous with our advice. But few interventions come without
ost and many have side effects. The principal arguments against
ffering universal (as opposed to personalized) prevention are cost
nd side effects. For imaging it is mostly about costs; for chemo-
revention it is mostly about side effects.
opulation stratiﬁcation for screening purposesThe premise underlying the personalized approach is that we
ill prevent more cancers for the same money if we categorize
∗ Correspondence to: Women’s College Research Institute, 790 Bay Street, Room
50,  Toronto, Ontario, Canada M5G  1N8. Tel.: +1 416 351 3675;
ax: +1 416 351 3767.
E-mail address: steven.narod@wchospital.ca
ttp://dx.doi.org/10.1016/j.jcpo.2014.05.002
213-5383/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article u
http://creativecommons.org/licenses/by-nc-nd/3.0/).people and ration wisely. But if mammography works why  not
offer it to everybody? The ﬁrst division of the population into
risk strata was based on age alone; in some places the age cut-
off for mammography was  forty, elsewhere ﬁfty. After 40 years we
are not sure if this simple policy is effective [1–3] and there is a
move afoot to replace it with something less simplistic. To some
extent, the case for a personalized approach to breast screening
may  be a reaction to what is perceived as an unsatisfactory outcome
with conventional screening. Some (like the Swiss) argue, based on
recent results from the Canadian Breast Cancer Screening Study,
that mammography should be scrapped [3]. Vehement support-
ers of mammography claim the Canadian study was fatally ﬂawed
and that we  should continue to screen as always [4–6]. But oth-
ers take a ‘middle ground’. They say that mammography does not
work as well as we would like when offered to all women and so
we should tailor screening according to level of risk. This argu-
ment is not based on logic or evidence, but is an opinion that once
heard, some people repeat when they wish to sound thoughtful. If
mammography is good for high-risk women but not for low-risk
women, then surely this would be because of false positives, high
costs, side effects and marginal beneﬁts – but these are not the
central issues – it is the lack of an observed mortality reduction
associated with early detection that belies the limits of mammog-
raphy. Mammography might work in high-risk women  but not in
low risk women if the biologic characteristics of the cancers were
different and not merely the prevalence. For example, small breast
cancers in BRCA1 carriers are more aggressive than average can-
cers [7] and over-diagnosis is less of a problem [8], but there is
also a high mortality associated with small node-negative heredi-
tary cancers [7] and there is little correlation between tumor size
and survival for small BRCA1-positive cancers [7,9]. MRI  has now
been adopted widely for screening of mutation carriers [10,11].
Studies to date that support the use of MRI  in BRCA1 carriers are
based on sensitivity [12–14] and not on mortality and we  should
not take a mortality beneﬁt for granted. One study from Norway
found that of 68 women  with a BRCA1 mutation and breast can-
cer detected through MRI, ten succumbed to their disease, despite
being diagnosed early [15].
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ersonal predictive genotypes
It is possible to prevent breast cancer in BRCA1 carriers through
rophylactic mastectomy [16], oophorectomy [17] and tamoxifen
18]. But BRCA1 variants are rare and only one in 500 Cana-
ian women are at risk because of one. There are many other
enetic variants that increase one’s risk of cancer. They may  be
n a highly penetrant gene (e.g. BRCA2), in a moderately penetrant
ene (such as CHEK2) or in a low penetrant gene (single nucleotide
olymorphism). It has been supposed for a decade now that com-
on, low penetrant genetic variants may  have greater population
ttributable risks than genes like BRCA1 [19]. There are thousands
f SNPs scattered throughout the genome – some are located in
enes, some are in nearby gene regulatory regions and some are in
laces where they have no clear impact on gene expression or func-
ion. Through a series of rigorous and comprehensive genome-wide
ssociation studies (GWAS) involving thousands of SNPs, thousands
f cases and controls (and hundreds of authors), 100 or so SNPs have
een shown to be reliable predictors of breast cancer risk [20–22].
he prevalence of the high risk alleles in general fall between 1%
nd 30% and the relative risks fall between 1.1 and 1.4. For a single
NP, the population risk attributable is below 3%. However, assum-
ng a multiplicative model, a panel of ten or more SNPs might be
sed to assign women to a high (or low) risk. For example, if each
f ten SNPs has a prevalence of 0.10, a relative risk of 1.2 for the risk
llele and a relative risk of 0.95 for the low risk allele (compared
o untested women), then a woman with ﬁve of ten possible risk
lleles would have a composite risk ratio of about two. But only two
n 1000 women in the population would have a risk of two-fold or
igher.
The translational promise from all of this work on SNPs is that we
an use personal predictive genotyping to tailor screening (lifestyle
s not on issue, one must eat well and exercise frequently regardless
f one’s genotype. No-one is serious enough to propose preven-
ive mastectomy on the basis of a few SNPs, and healthy women
t much higher levels of risk rarely take tamoxifen). In the case
f SNPs, screening is the best medicine. Hence it is proposed that
omen at high a priori risk should either qualify for MRI  screening
r go for mammograms early. In Ontario, MRI  is expensive and
 25% lifetime risk is the current requirement. An alternate pro-
osal is that women at high risk based on a predictive genetic test
esult be offered mammography from age 40, not 50. Consider a
cenario wherein the top one percentile of the population expe-
iences a twofold increase in risk. If ten percent of the women  in
anada opt to pay for the test (or have it paid for them) then one
n 1000 Canadian women will be found to be at high risk. Suppose,
or them, screening begins at age 40 instead of age 50. The cumu-
ative incidence of breast cancer from age 40 to 50 is about 1% in
anada, and doubling it will raise it to 2%. If screening is associated
ith a 30% reduction in mortality and if the baseline case fatality
f breast cancer is 30%, then we can expect to save the lives of two
omen in a million as a result of the new program (and 40,000
ther Canadian women will die of breast cancer nevertheless). It
s perhaps not unexpected, that given the enormous cost of the
WAS enterprise, in terms of hard cash and intellectual currency,
hat the proponents of genetic risk stratiﬁcation should support the
NP paradigm despite having neither evidence nor promise.
ersonalized medicine in the clinic
For some risk factors, such as family history, age of menarche,
arity and breastfeeding, exposure status will be known by almost
00% of women at the time of the clinic visit and it requires little
r no investment to retrieve the relevant information. Other risk
actors, such as mammographic density and atypical hyperplasia Policy 2 (2014) 93–96
require an investment in time, cost and perhaps morbidity. Very
few women know their mammographic density and most women
with atypical hyperplasia are unaware of it. In order to ascertain
one’s genetic risk stratum, one needs to undergo a genetic test.
The test result will need to be interpreted and explained. Perhaps
a genetic counselor should be involved. The underlying premise
of genetic risk stratiﬁcation is that all women in the population
are candidates for the upfront test; women are not pre-selected
based on disease status or on family history. If genetic counsel-
ing is indicated, then we  are committed to offering counseling to
all. The process will be further complicated if the patient also has a
family history, because it will be necessary for a professional to sort
out both the family history and the genotype information. Should
someone high up in the health care system decide that it is accept-
able to withhold screening to women based on a low personal risk
then someone else will have to explain this to the patient, who may
or may  not welcome the news. If the test is offered to all women, is
it likely to be included as part of a national health care system or to
be reimbursed by a third-party payer? Perhaps the woman  herself
will pay for the test. How many will pay? I guess the number will
be below ten percent, perhaps as low as one percent. If a private
company can market a genetic test to 10% of the general population
then it would be ﬁnancially successful, but if a public health unit
enrolled only 10% of the target population in a screening program
then it would probably be considered a failure. If the goal of a cancer
prevention initiative is to reduce the incidence of cancer in the pop-
ulation then a reduction in incidence should be the criterion under
which the program is evaluated. Predictive genetic testing can, in
some cases, generate odds ratios that are clinically meaningful, but
even a cursory analysis of the public health implications of genetic
risk stratiﬁcation compels the conclusion that this will have little
or no impact on cancer rates. The promise of personalized medicine
was to identify a simple test that could categorize the majority of
potential cases within a subgroup of the population. If they gave us
a risk classiﬁer that would correctly predict 90% of breast cancers
in ten percent of the population, the promise would be fulﬁlled.
But that would entail an odds ratio of 81 for a risk factor with a
prevalence of 10%. Instead we are given an odds ratio of two with
a prevalence of 1%.
Potential for reducing cancer incidence in BRCA mutation
carriers
Arguably one of the most effective strategies available at present
for preventing cancer is to offer preventive oophorectomy to
women with a BRCA1 or BRCA2 mutation [17]. 13% of women with
ovarian cancer have a mutation [23] and these are potentially pre-
ventable if the mutation could be identiﬁed prior to diagnosis. This
would require a genetic testing policy that would include 100% of
carriers as eligible for testing and a referral mechanism that would
identify them and refer them for testing. Furthermore, the patients
would wish to have genetic testing and in the event of a positive
test, agree to oophorectomy. In a recent study from Ontario, we
have shown that 3.6% of women with ovarian cancer were eligi-
ble for genetic testing prior to the test [24]. This implies that if all
eligible women  were identiﬁed and referred for testing and were
subsequently tested and accepted oophorectomy, and if oophorec-
tomy were 100% effective, then we could prevent 3.6% of cases (36
cases a year in Ontario). Realistically, suppose that only 20% of eli-
gible women  were recognized as such and offered testing, of whom
80% accepted, 75% had an oophorectomy and that oophorectomy
was 80% effective, then the fraction of cancers prevented drops to
one in 300, or four cases annually in Ontario (far less than one
percent). The reality of tamoxifen chemoprevention is even less
impressive. Assume that 5% of women  with breast cancer have a
ancer
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RCA1 or BRCA2 mutation and that one in ten women  with a muta-
ion is aware of her mutation status prior to diagnosis. Currently
bout 5% of healthy women with a BRCA mutation take tamoxifen
25]. Suppose that tamoxifen reduces the incidence of breast cancer
n BRCA carriers by 50%. On a population level, the program would
revent one in 8000 cases in Ontario, or roughly one case of breast
ancer per year.
ther high risk genes
BRCA1 is a high-risk gene and the clinical beneﬁt from testing
s largely attributable to oophorectomy. Oophorectomy is com-
on  among carriers and prevents ovarian cancer, breast cancer and
eath from breast cancer [17]. Mastectomy is also effective [16] but
he uptake is far less [25].
For genes such as CHEK2, ovarian cancer does not feature and
ophorectomy is not proposed; prevention relies on tamoxifen and
creening [26]. CHEK2 testing is not yet widespread and there is
o evidence that testing for CHEK2 will have an impact on can-
er risk. Several companies offer genetic panel testing for a larger
umber of genes associated with an increased breast cancer risk,
ncluding CHEK2, but testing for these is currently limited to a
ew women and the clinical utility has not been shown. In one
tudy reported to date, 198 women who had qualiﬁed for test-
ng for BRCA1 and BRCA2 were offered extended panel testing for
2 cancer related genes, including BRCA1, BRCA2 and 40 other
enes [27]. Of these, 57 carried a BRCA1 or BRCA2 mutation and
ix women carried a mutation in another breast cancer gene (ATM,
LM, CDH1, NBN and SLX4). These six women were advised to con-
ider annual MRIs because of an (estimated) doubling of cancer
isk (even though several already had breast cancer). There was
o discussion of tamoxifen or preventive mastectomy. The authors
onclude that “these results suggest that multiple-gene testing may
eneﬁt appropriately selected patients.” I have no idea how they
eached this conclusion.
hould we  adopt a personalized approach?
There is insufﬁcient data to support a publicly funded health ini-
iative based on personal genotyping with SNPs. The odds ratios are
ar too small to be useful, even in combination, and yet there is the
otential to greatly increase the quantity of genetics and counseling
elivered. The costs of the counseling, genotyping and additional
maging cannot be justiﬁed based on the expectation of lives saved
r cancers prevented. To a large extent, the current clinical position
 which is adopted by the majority in the clinical cancer genet-
cs community, reﬂects an attempt to justify the past expense of
he GWAS studies and to translate these ﬁndings into clinical care.
he GWAS studies were driven by innovation in technology and
he widespread public attention garnered by the human genome
equencing initiative. The development of a comprehensive map  of
uman polymorphic variation and the release of chip-based tech-
ologies made it possible to evaluate many loci simultaneously and
t was expected that these studies would reveal the inner nature of
ancer susceptibility. It is too early to say if the genes identiﬁed
hrough these studies will eventually lead to a sufﬁcient number of
seful drugs to justify the expense.
Genetic testing for the two high-risk genes BRCA1 and BRCA2
an clearly beneﬁt individual patients. The majority of beneﬁts are
ttributable to oophorectomy and mastectomy, and the beneﬁts of
amoxifen or MRI  screening have yet to be demonstrated. Never-
heless in terms of the entire population, unless testing becomes
niversal, under current protocols we cannot expect to experience
 decline in breast or ovarian cancer risk that exceeds one per-
ent of the baseline incidence after the introduction of a genetic
[
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test for BRCA1 and BRCA2. Exceptions may  be in countries with
high prevalence of founder mutations such as Israel [28] and the
Bahamas [29]. A second wave of technologic innovation (next gen-
eration sequencing) and the reversal in the courts of the Myriad
patent position led to a rapid expansion of the number of providers
of genetic testing and in the spirit of competition has led to a transi-
tion from two-gene testing (BRCA1 and BRCA2) to multigene panel
testing. Mutations in these supplemented genes are rare. For most
of these, the risk estimates for breast cancer risk are low (or impre-
cise) and mastectomies will be uncommon. For most of these, the
risk of ovarian cancer is too low to prompt oophorectomy. Given
the rarity of mutations and the reliance on screening and tamoxifen
for women with mutations in these genes, the addition of multiple
genes to the basic BRCA1 and BRCA2 test through comprehensive
panels is not likely to prevent very many breast cancers. Individ-
ual patients may  beneﬁt but national cancer incidence rates will be
unperturbed.
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